Elobixibat

# Elobixibat ## Overview - **Classification**: Ileal Bile Acid Transporter (IBAT) Inhibitor - **Mechanism**: Inhibits the transport of bile acids from the intestinal lumen into the enterocyte in the terminal ileum, increasing fecal excretion of bile acids. ## Primary Indications 1. **Chronic Constipation (CC)**: Used when traditional laxatives are ineffective. 2. **Post-Hepatitis C Treatment Cholestatic Pruritus** (Off-label/Investigational). ## Adult Dosing ### Standard Dosing **Chronic Constipation (CC)** - **Dose**: **5 mg** - **Frequency**: Once daily (QD) - **Route**: Oral (PO) - **Timing**: Taken preferably at breakfast. ### Dose Adjustments - **Renal Impairment**: No dose adjustment is typically required. - **Hepatic Impairment**: - **Mild (Child-Pugh A)**: No adjustment needed. - **Moderate (Child-Pugh B)**: Start at **5 mg** QD; monitor closely. - **Severe (Child-Pugh C)**: Use is generally **not recommended** due to lack of data. - **Elderly Patients**: No specific dose adjustment needed; start low and monitor hydration. ## Pediatric Dosing *Note: Elobixibat is generally not recommended or approved for routine use in pediatric patients for chronic constipation in most regions.* ### Neonates (0-28 days) - **Dose**: Safety and efficacy **not established**. - **Special Notes**: Contraindicated in infants with biliary atresia; risk of serious dehydration. ### Infants (1-12 months) - **Dose**: Safety and efficacy **not established**. - **Special Notes**: Avoid use; risk of severe diarrhea and electrolyte loss. ### Children (1-12 years) - **Dose**: Safety and efficacy **not established**. - **Maximum**: **Do not exceed 5 mg** if used investigational (under strict medical supervision). ### Adolescents (13-18 years) - **Dose**: If constipation persists, may follow the adult dosing regimen (**5 mg** PO QD). - **Maximum**: **5 mg** per day. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to elobixibat or excipients. - **Absolute**: Patients with known or suspected **mechanical gastrointestinal obstruction**. - **Absolute**: Symptoms of acute abdomen (e.g., appendicitis). ### Common Adverse Effects - **Very Common (>10%)**: Diarrhea, Abdominal pain. - **Common (1-10%)**: Nausea, Abdominal distention, Flatulence. - **Serious but Rare**: Severe persistent diarrhea leading to dehydration and electrolyte imbalance. ### Key Drug Interactions - **Bile Acid Sequestrants (e.g., Cholestyramine)**: Significantly reduces elobixibat absorption and effectiveness. **Separate administration by 4 hours**. - **P-gp Substrates (e.g., Digoxin)**: Elobixibat may increase systemic exposure of P-gp substrates; monitor narrow therapeutic index drugs. - **Fat-soluble Vitamins (A, D, E, K)**: Potential for reduced absorption with long-term use; monitor levels if deficiency is suspected. ## Monitoring & Follow-up - **Before Treatment**: Assess for signs of GI obstruction or acute abdominal symptoms. - **During Treatment**: Monitor frequency and consistency of stools (daily assessment). - **During Treatment**: Monitor for signs of dehydration (e.g., dry mouth, decreased urination). - **Clinical Signs**: Watch for severe, watery diarrhea or worsening abdominal pain. ## Clinical Pearls - 💡 **Tip 1**: Start at the standard dose (**5 mg**). Only increase if needed and diarrhea is not present (max 10 mg/day if approved by local guidelines). - 💡 **Tip 2**: The onset of action is generally within 24 hours. The full effect may take 1-2 weeks. - 💡 **Tip 3**: Emphasize adequate **hydration** to the patient, especially if diarrhea occurs. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.